{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:41:51Z","timestamp":1790707311158,"version":"4.1.0"},"reference-count":58,"publisher":"Wiley","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Heart failure (HF) imposes a substantial economic burden, especially among populations with comorbidities in China. Sotagliflozin has shown clinical benefits in HF patients with type 2 diabetes mellitus (T2DM). This study evaluated the cost\u2010utility of sotagliflozin in China and explored pricing strategies to support its potential market entry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multistate Markov model was developed to assess the cost\u2010utility of adding sotagliflozin to standard therapy in HF\u2010T2DM patients, using data from the SOLOIST\u2010WHF trial. A hypothetical cohort of 1000 patients was simulated, with transition probabilities adjusted for the Chinese population. Costs and utilities were derived from Chinese sources where available, and both outcomes and costs were discounted at 5% annually. Deterministic, probabilistic and scenario\u2010based sensitivity analyses were conducted to assess uncertainty and evaluate alternative pricing scenarios.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>In the base\u2010case analysis, the incremental cost\u2010utility ratio of sotagliflozin was $50,072.77 per QALY, exceeding the Chinese willingness\u2010to\u2010pay threshold of $37,864. Deterministic analysis identified cardiovascular mortality in the control group as the most influential parameter. Probabilistic analysis showed a 38.84% probability of cost\u2010utility. A 22.7% price reduction would be required for sotagliflozin to meet cost\u2010effectiveness thresholds. Varying treatment duration did not change this outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study found that sotagliflozin is not cost\u2010effective for HF\u2010T2DM patients in China at current prices. Its economic value is highly sensitive to drug cost, highlighting the need for localized pricing strategies. These findings can inform future reimbursement decisions and support value\u2010based market entry planning.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bcp.70187","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T11:43:45Z","timestamp":1754135025000},"source":"Crossref","is-referenced-by-count":1,"title":["Cost\u2013utility analysis of sotagliflozin for heart failure patients with diabetes in China"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-1917","authenticated-orcid":false,"given":"Xinyue","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration School of Pharmaceutical Sciences, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyi","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration School of Pharmaceutical Sciences, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy the Affiliated Hospital of Xuzhou Medical University  Xuzhou Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunrong","family":"Shen","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes and PharmacoEconomic Research, University of Arizona  Tucson AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Guo","sequence":"additional","affiliation":[{"name":"Minhang Hospital &amp; Department of Clinical Pharmacy School of Pharmacy, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijia","family":"Tang","sequence":"additional","affiliation":[{"name":"Shanghai Center for Adverse Drug and Medical Device Reaction Monitoring  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aole","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration School of Pharmaceutical Sciences, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-619X","authenticated-orcid":false,"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration School of Pharmaceutical Sciences, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration School of Pharmaceutical Sciences, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-1550","authenticated-orcid":false,"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration School of Pharmaceutical Sciences, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569\u2010024\u201001046\u20106"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001123"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013"},{"issue":"3","key":"e_1_2_11_5_1","first-page":"221","article-title":"2020 China heart failure medical quality control report","volume":"36","author":"Working Group on Heart Failure NCfCQI","year":"2021","journal-title":"J China Circ"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14047"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24\u2010S010"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12782"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn153"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:20:2"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.478"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12844"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14426"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd\u201022\u2010463"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256\u2010022\u201000550\u20109"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010019\u20100828\u2010y"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183"},{"key":"e_1_2_11_22_1","unstructured":"CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: 216203Orig1s0002023. Accessed March 13 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216203Orig1s000Approv.pdf"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/m21\u20100651"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008406"},{"key":"e_1_2_11_25_1","unstructured":"National Institute for Health and Care Excellence.Technology appraisal guidance [TA388]: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. April 2 2025. Accessed April 2 2025.https:\/\/www.nice.org.uk\/guidance\/ta388\/chapter\/3-Evidence#cost-effectiveness-evidence"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1978"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2054226"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_2_11_29_1","unstructured":"Chinese Pharmaceutical Association.2020China Guidelines for Pharmacoeconomic Evaluations (2020)"},{"key":"e_1_2_11_30_1","unstructured":"National Bureau of statistics.China Statistical Yearbook 2024. 23th April 2025.2024. Accessed April 23 2025.https:\/\/www.stats.gov.cn\/sj\/ndsj\/2024\/indexch.htm"},{"key":"e_1_2_11_31_1","unstructured":"Chinese Center for Disease Control and Prevention.China Mortality Surveillance Dataset15 March 2025. Accessed March 15 2025.https:\/\/ncncd.chinacdc.cn\/jcysj\/siyinjcx\/syfxbg\/202403\/W020230317353700905354.pdf"},{"issue":"6","key":"e_1_2_11_32_1","first-page":"974","article-title":"Influence of heart transplantation on the natural history of patients with severe congestive heart failure","volume":"12","author":"Anguita M","year":"1993","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x16656165"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","DOI":"10.1002\/9781119942986","volume-title":"Evidence synthesis for decision making in healthcare","author":"Welton NJ","year":"2012"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.48172"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.03.021"},{"key":"e_1_2_11_37_1","unstructured":"National Health Commission of China.China Health Statistical Yearbook2022.2022. Accessed March 13 2025.http:\/\/www.nhc.gov.cn\/mohwsbwstjxxzx\/tjtjnj\/202305\/6ef68aac6bd14c1eb9375e01a0faa1fb\/files\/b05b3d958fc546d98261d165cea4adba.pdf"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1297309"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.19546\/j.issn.1674\u20103830.2017.3.013"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.02.007"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.04.018"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer\u20102023\u20100190"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.860109"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14501"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.08.017"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010021\u201001387\u20103"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13583"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.1437"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.3402\/jmahp.v4.30458"},{"key":"e_1_2_11_50_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-031-61901-4_5","volume-title":"China Food and Drug Law: Policy, Practice, and Future Directions","author":"Balzano JC","year":"2024"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2016.03.014"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh\u20102021\u2010005519"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20104733.2009.00662.x"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2214\u2010109x(23)00162\u20106"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.751176"},{"issue":"1","key":"e_1_2_11_56_1","first-page":"62","article-title":"The challenge of paying for cost\u2010effective cures","volume":"23","author":"Zettler PJ","year":"2017","journal-title":"Am J Manag Care"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2223984"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.indmarman.2003.10.006"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/hcs2.76"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T11:43:49Z","timestamp":1754135029000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":58,"alternative-id":["10.1002\/bcp.70187"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70187","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"article-number":"bcp.70187"}}